New collaboration launched to support the development of vaccines against henipavirus

Sanofi is clos­ing an ex-Kymab re­search and de­vel­op­ment site in Cam­bridge, UK, which could see job loss­es for 90 staffers, a com­pa­ny spokesper­son told End­points

Sanofi’s an­ti-OX40L an­ti­body, am­lite­limab, passed a 390-pa­tient Phase IIb tri­al by hit­ting the pri­ma­ry end­point, with pa­tients see­ing up to a 61.5% im­prove­ment on a